Liposomal formulations were obtained mixing 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) with synthetic lovastatin or lovastatin extracted from Red Yeast Rice (RYR) to prepare a vehicle able to overcome both the disadvantage of lovastatin, i.e its poor oral bioavailability and side effects. Liposomal formulation obtained combining DOPC, DOPE and hydro-alcoholic extract of RYR showed optimal physico-chemical, mechanical and thermal characteristics and the strongest inhibition activity versus 3-hydroxy-3-Methyl glutaryl coenzyme A (HMG-CoA) reductase.

Leone, G., Consumi, M., Franzi, C., Tamasi, G., Lamponi, S., Donati, A., et al. (2018). Development of liposomal formulations to potentiate natural lovastatin inhibitory activity towards 3-hydroxy-3-methyl-glutaryl coenzyme A (HMGCoA) reductase. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 43, 107-112 [10.1016/j.jddst.2017.09.019].

Development of liposomal formulations to potentiate natural lovastatin inhibitory activity towards 3-hydroxy-3-methyl-glutaryl coenzyme A (HMGCoA) reductase

Gemma, Leone;Consumi, Marco;Tamasi, Gabriella;Lamponi, Stefania;Donati, Alessandro;Magnani, Agnese;Rossi, Claudio;Bonechi, Claudia
2018-01-01

Abstract

Liposomal formulations were obtained mixing 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) with synthetic lovastatin or lovastatin extracted from Red Yeast Rice (RYR) to prepare a vehicle able to overcome both the disadvantage of lovastatin, i.e its poor oral bioavailability and side effects. Liposomal formulation obtained combining DOPC, DOPE and hydro-alcoholic extract of RYR showed optimal physico-chemical, mechanical and thermal characteristics and the strongest inhibition activity versus 3-hydroxy-3-Methyl glutaryl coenzyme A (HMG-CoA) reductase.
Leone, G., Consumi, M., Franzi, C., Tamasi, G., Lamponi, S., Donati, A., et al. (2018). Development of liposomal formulations to potentiate natural lovastatin inhibitory activity towards 3-hydroxy-3-methyl-glutaryl coenzyme A (HMGCoA) reductase. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 43, 107-112 [10.1016/j.jddst.2017.09.019].
File in questo prodotto:
File Dimensione Formato  
Lipo_JDDST.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 350.79 kB
Formato Adobe PDF
350.79 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
DONATI A-Development of liposomal-Post--Print.pdf

accesso aperto

Descrizione: Accepted Manuscript
Tipologia: Post-print
Licenza: Creative commons
Dimensione 1.08 MB
Formato Adobe PDF
1.08 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1019159